Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Feb;10(2):90-9.
doi: 10.1038/nrclinonc.2012.209. Epub 2012 Dec 4.

Understanding the mechanisms and treatment options in cancer cachexia

Kenneth Fearon  1 , Jann Arends, Vickie Baracos
Affiliations
Review

Understanding the mechanisms and treatment options in cancer cachexia

Kenneth Fearon et al. Nat Rev Clin Oncol. 2013 Feb.

Abstract

Cancer cachexia is a metabolic syndrome that can be present even in the absence of weight loss ('precachexia'). Cachexia is often compounded by pre-existing muscle loss, and is exacerbated by cancer therapy. Furthermore, cachexia is frequently obscured by obesity, leading to under-diagnosis and excess mortality. Muscle wasting (the signal event in cachexia) is associated not only with reduced quality of life, but also markedly increased toxicity from chemotherapy. Many of the primary events driving cachexia are likely mediated via the central nervous system and include inflammation-related anorexia and hypoanabolism or hypercatabolism. Treatment of cachexia should be initiated early. In addition to active management of secondary causes of anorexia (such as pain and nausea), therapy should target reduced food intake (nutritional support), inflammation-related metabolic change (anti-inflammatory drugs or nutrients) and reduced physical activity (resistance exercise). Advances in the understanding of the molecular biology of the brain, immune system and skeletal muscle have provided novel targets for the treatment of cachexia. The combination of therapies into a standard multimodal package coupled with the development of novel therapeutics promises a new era in supportive oncology whereby quality of life and tolerance to cancer therapy could be improved considerably.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Curr Cancer Drug Targets. 2012 May;12(4):372-90 - PubMed
    1. Int J Oncol. 2004 Mar;24(3):505-12 - PubMed
    1. Cell. 2010 Aug 20;142(4):531-43 - PubMed
    1. J Clin Endocrinol Metab. 2004 Jun;89(6):2832-6 - PubMed
    1. Can J Surg. 2001 Apr;44(2):102-11 - PubMed

LinkOut - more resources